- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT07432958
레보도파를 보조요법으로 사용하는 파킨슨병 환자의 운동 변동성을 평가하기 위한 AP-472 두 용량의 효과성 연구
운동 변동성을 보이는 파킨슨병(PD) 참가자에서 레보도파의 부가 요법으로 AP-472의 두 용량의 효과를 평가하기 위한 2상, 이중 맹검, 위약 대조 연구
This is a Phase 2 study in people with Parkinson's disease who experience motor fluctuations while taking levodopa. The study will evaluate how effective two different doses of the study drug AP-472 are when added to levodopa treatment, compared with a placebo.
The study will last about 14 weeks. Participants will be randomly assigned to receive one of the two doses of AP-472 or a placebo. Neither the participants nor the study staff will know which treatment is given.
The study includes a screening period, a 4-week period during which Parkinson's medications must remain stable, and a 12-week treatment period. During the treatment period, limited adjustments to levodopa are allowed if needed.
연구 개요
연구 유형
등록 (추정된)
단계
- 2 단계
연락처 및 위치
연구 연락처
- 이름: Annie Blobaum, Ph.D.
- 전화번호: 615-427-1935
- 이메일: annie@appellopharma.com
연구 장소
-
-
Arkansas
-
Little Rock, Arkansas, 미국, 72205-5551
- 모병
- University of Arkansas for Medical Sciences (Site #208)
-
-
California
-
Carlsbad, California, 미국, 92011
- 모병
- Profound Research LLC (Site #222)
-
Los Alamitos, California, 미국, 90720-3108
- 모병
- Collaborative Neuroscience Network - Los Alamitos- CenExel - PPDS (Site #217)
-
Los Angeles, California, 미국, 90033-5310
- 모병
- Keck Medicine of USC - USC Healthcare Center 2 (Site #221)
-
Palo Alto, California, 미국, 94301
- 모병
- Parkinson's Research Centers of America (Site #218)
-
-
Colorado
-
Englewood, Colorado, 미국, 80113-2776
- 모병
- Rocky Mountain Clinical Research - CenExel - PPDS (Site #215)
-
-
Florida
-
Boca Raton, Florida, 미국, 33486
- 모병
- Parkinson's Disease & Movement Disorders Center of Boca Raton (Site #227)
-
Boca Raton, Florida, 미국, 33486
- 모병
- UM-UHealth at Boca Raton (Site #226)
-
Hallandale, Florida, 미국, 33009
- 모병
- Velocity Clinical Research - Hallandale Beach (Site #228)
-
Miami, Florida, 미국, 33136-1051
- 모병
- University of Miami (Site #220)
-
Orlando, Florida, 미국, 32825
- 모병
- Neurology One (Site #205)
-
Tampa, Florida, 미국, 33613-4808
- 모병
- USF Parkinson's Disease and Movement Disorders Center (Site #206)
-
-
Georgia
-
Augusta, Georgia, 미국, 30912-0020
- 모병
- Augusta University Medical Center (Site #212)
-
-
Indiana
-
Indianapolis, Indiana, 미국, 46256
- 모병
- Josephson Wallack Munshower Neurology PC (Site #231)
-
-
Kansas
-
Kansas City, Kansas, 미국, 66160
- 모병
- The University of Kansas (KU) (Site #216)
-
-
Kentucky
-
Lexington, Kentucky, 미국, 40536-0001
- 모병
- Kentucky Neuroscience Institute (Site #213)
-
-
Massachusetts
-
Boston, Massachusetts, 미국, 02215-5400
- 모병
- Beth Israel Deaconess Medical Center (Site #211)
-
-
Michigan
-
Ann Arbor, Michigan, 미국, 48109
- 모병
- University of Michigan Health System (UMHS) (Site #202)
-
Farmington Hills, Michigan, 미국, 48334-2973
- 모병
- Quest Research Institute - Alcanza - PPDS (Site #201)
-
-
New Mexico
-
Albuquerque, New Mexico, 미국, 87106
- 모병
- University of New Mexico Health Sciences Center (Site #225)
-
-
New York
-
New York, New York, 미국, 10029-6501
- 모병
- Mount Sinai School of Medicine (Site #209)
-
New York, New York, 미국, 10021
- 모병
- Joan and Sanford I. Weill Department of Medicine (Site #224)
-
-
North Carolina
-
Asheville, North Carolina, 미국, 28806
- 모병
- Asheville Neurology Specialists, P.A. (Site #229)
-
Durham, North Carolina, 미국, 27705
- 모병
- Duke Neurological Disorders Clinic (Site #210)
-
-
Ohio
-
Cleveland, Ohio, 미국, 44195-0001
- 모병
- Cleveland Clinic (Site #223)
-
Columbus, Ohio, 미국, 43210
- 모병
- The Ohio State University Wexner Medical Center (site #207)
-
-
Tennessee
-
Nashville, Tennessee, 미국, 37232
- 모병
- Vanderbilt University Medical Center (Site #204)
-
-
Texas
-
Cypress, Texas, 미국, 77429
- 모병
- Horizon Clinical Research: Gill Neuroscience - Houston (Site #232)
-
Round Rock, Texas, 미국, 78681-3578
- 모병
- Central Texas Neurology Consultants (Site #203)
-
-
Washington
-
Kirkland, Washington, 미국, 98034-3013
- 모병
- EvergreenHealth (Site #219)
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Key Inclusion Criteria:
Participants must meet all of the following criteria to take part in the study:
- Be a man or woman between 30 and 80 years of age at the time of screening.
- Have a diagnosis of Parkinson's disease, confirmed using standard medical criteria, including slowness of movement and symptoms that affect one side of the body more than the other.
- Have mild to moderate Parkinson's disease, defined as stage 3 or lower on the Hoehn and Yahr scale when medications are working ("ON" state).
- Experience an average of at least 3 hours of OFF time per day, based on home symptom diaries, with at least 2.5 hours of OFF time each day during the baseline period.
- Have a Montreal Cognitive Assessment (MoCA) score of 24 or higher at screening.
- Be able to walk independently, with or without the use of a walking aid.
- Be able to swallow oral medication.
- Have been on a stable Parkinson's medication regimen for at least 4 weeks before screening. Medications known as MAO-B inhibitors must have been stable for at least 12 weeks.
- Be taking levodopa at least four times daily (immediate- or controlled-release formulations) or three times daily (extended-release formulations such as Rytary or Crexont).
Key Exclusion Criteria:
Participants cannot take part in the study if any of the following apply:
- Have a form of parkinsonism that is not typical Parkinson's disease, such as secondary or atypical parkinsonism.
- Have previously received, or plan to receive during the study, advanced Parkinson's therapies such as continuous levodopa or dopamine delivery systems, or Parkinson's disease-related brain surgery.
- Have dyskinesias (involuntary movements) that are severe enough, in the study doctor's opinion, to interfere with participation.
- Have a history of only certain types of dyskinesias (such as OFF-state, diphasic, myoclonic, or dystonic dyskinesias) without typical peak-dose dyskinesias.
- Are currently taking medications that block dopamine, except for low-dose quetiapine (up to 50 mg per day) used for insomnia.
- Routinely use on-demand "rescue" Parkinson's medications more than three times per week.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 더블
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
위약 비교기: 위약
|
Oral tablet |
|
실험적: Low Dose
AP-472 100 mg per day |
Oral tablet Oral tablet |
|
실험적: High Dose
AP-472 300 mg per day |
Oral tablet |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
기간 |
|---|---|
|
AP-472 대 위약군 비교 시 모터 일지 기준 평균 일일 OFF 시간의 기저선 대비 변화 (16시간 깨어 있는 시간으로 정규화)
기간: 12주차
|
12주차
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
기저선 대비 성가신 이상운동증이 없는 ON 시간 변화(16시간으로 정규화됨)
기간: 12주차
|
12주차
|
|
|
Change from baseline in Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part 2 (Motor Experiences of Daily Living (M-EDL)) score
기간: Week 12
|
For MDS-UPDRS Part II (Motor Experiences of Daily Living, M-EDL) there are 13 items each scored from 0 to 4. The total score range is from 0-52. A higher score indicates worse motor impact on daily activities; lower scores are better. |
Week 12
|
|
Change from baseline in Parkinson's Disease Questionnaire-39 (PDQ-39) summary index
기간: Week 12
|
For the Parkinson's Disease Questionnaire-39 (PDQ-39) Summary Index the score is calculated by averaging the 8 domain scores and converting them to a 0-100 scale. A higher score indicates worse health-related quality of life; lower scores are better. |
Week 12
|
|
Change from baseline in MDS-UPDRS Part III (Motor Examination) score in the best ON state
기간: Week 12
|
The MDS-UPDRS Part III includes 33 items, each scored from 0 to 4. The total score range is from 0-132. A higher score indicates worse motor impairment; lower scores are better. |
Week 12
|
|
Change from baseline in Epworth Sleepiness Scale (ESS) total score
기간: Week 12
|
The ESS consists of 8 items, each scored from 0 to 3. The total score range is from 0-24. Higher scores indicate greater daytime sleepiness; lower scores are better. |
Week 12
|
공동 작업자 및 조사자
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- APLO-1201
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .